Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06752668 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Study acronym: CRYSTAL-1
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment target: 96 to 248
    • Primary and study completion dates: Dec 2025 to Dec 2026
    • Study sites: 29 to 37
    • Secondary endpoints revised (7)
    v12
  2. Minor Study sites: 28 to 29v11
  3. Minor Study sites: 26 to 28v10
  4. Minor Study sites: 25 to 26v9
  5. Minor Enrollment target: 78 to 96v8
Show 6 earlier versionsHide 6 earlier versions
  1. Minor Study sites: 20 to 25v7
  2. Minor Site details revised at 2 of 20 sitesv6
  3. Minor Study sites: 12 to 20v5
  4. Minor Site details revised at 1 of 12 sitesv4
  5. Minor Site details revised at 1 of 12 sitesv3
  6. Minor Study sites: 1 to 12v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities. While all conditions result in feeling sleepy, there are some differences in other common symptoms: * NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night. * NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy. * IH: People with IH feel tired during the day, even after sleeping a lot at night. They may sleep for long periods, take long naps, and find it hard to wake up. Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton (also known as ORX750) is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable ORX750 is in NT1, NT2, and IH, and learn about what the drug does to the body. Another goal of the study is to see if ORX750 can help people with NT1, NT2, and IH feel less sleepy and make other symptoms better.
Trial Details
NCT Number NCT06752668
Lead Sponsor Centessa Pharmaceuticals (UK) Limited
Conditions
(from sponsor)
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Related terms Idiopathic Hypersomnia
Enrollment 248 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov